Abstracts tagged "autoimmune diseases and toll-like receptors"

Abstract Number: 21 • 2018 ACR/ARHP Annual Meeting
Elevated EPSTI1 Promote B Cells Hyperactivation through NF-Kb Signaling in Patients with Sjögren ’s Syndrome
Jin-Lei Sun¹, Zhi-Lei Chen², Chao-Feng Lian³, Ti-Hong Shao², Hao-Ze Zhang², Hua Chen³ and Feng-Chun Zhang², ¹Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China, ²Peking Union Medical College Hospital, Beijing, China, ³Rheumatology, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Sjogren's syndrome (SS) is a common systemic autoimmune disease characterized with aberrant B cells activation. B cells play a key role in the pathogenesis…
Abstract Number: 1171 • 2013 ACR/ARHP Annual Meeting
Treatment Of Psoriasis Patients With IMO-3100 Shows Improvement In Gene Expression Patterns Of Meta-Analysis Derived-3 Transcriptome and IL-17 Pathway
Mayte Suarez-Farinas¹, Jennifer Belasco¹, Tim Sullivan², Robert Arbeit² and James G. Krueger¹, ¹Krueger Laboratory, The Rockefeller University, New York, NY, ²Idera Pharmaceuticals, Inc., Cambridge, MA

Background/Purpose: IMO‑3100, an antagonist of TLRs 7 and 9, has shown significant improvement in Psoriasis Area and Severity Index (PASI) scores in a randomized, double‑blind,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].